Compare Moody's Corporation (MCO) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs Travere Therapeutics Inc. Common Stock — how do they compare? Moody's Corporation trades at $467 (market cap $80.38B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Moody's Corporation is far larger — about 16.5× Travere Therapeutics Inc. Common Stock's market cap, and Moody's Corporation pays a 0.89% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moody's Corporation for 133 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| MCO | TVTX | |
|---|---|---|
Market Cap | $80.38B | $4.88B |
Volume | 628,586 | 1,668,577 |
Sector | Financials | Health |
52-Week High | $539.61 | $67.52 |
52-Week Low | $412.23 | $26.79 |
Typical Hold Time | 133 Days | 0 Days |
Enterprise Value | $86.40B | $5.01B |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moody's Corporation (MCO) trades at $462.77, down 1.64% on the day, as the stock consolidates near key support. The company maintains strong fundamentals with revenue reaching $7.72B in 2025 and net income margin expanding to 34.25%. Recent earnings beats and a bullish technical signal underscore positive momentum, while analyst consensus remains favorable with a $536.40 price target. Strategic moves like the PhilRatings stake and Google Cloud partnership highlight growth initiatives in the Asia-Pacific region and financial services technology.
Outlook: Moody's exhibits robust profitability and strategic expansion, supporting a positive investment case. Risks include high valuation multiples (P/E 29.45) and sensitivity to credit cycle fluctuations. The stock offers growth potential but requires monitoring of debt levels and macroeconomic trends affecting its credit rating business.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
